Croatian Society of Physical and Rehabilitation Medicine, Croatian Medical Association
Abstract
Reumatoidni artitis (RA) kronična je, upalna, autoimuna bolest od koje boluje približno 1% svjetske populacije. Složena mreža citokina odgovorna je za pokretanje i održavanje upalnih zbivanja u reumatoidnom artritisu. Ovaj pregled prikazuje najnovija saznanja o terapiji reumatoidnog artritisa lijekovima usmjerenim prema
tumor-necrosis factor-alpha (TNF-alfa), inhibitorima interleukin-1, te lijekovima usmjerenim prema stanicama T i B poput abatacepta i rituksimaba.Rheumatoid arthritis(RA) is a chronic, inflammatory, autoimmune disease wich affects approximately 1% of world population. Multiple cytokines operate as a network in a redundant and overlapping manner in rheumatoid artrhitis. This review highlights recent data on tumor-necrosis factor alpha (TNF-alfa), interleukin-1 inhibitors, as well as new biological agents abatacept and rituximab wich are specifically targeted
to T cells and to population of B cells
